Reliever Inhaled Glucocorticoid Treatment

Black and Latinx patients are disproportionately impacted by asthma. In fact, asthma mortality rates are twice as high in Black patients compared to White patients. Are there different treatment options to help improve mortality in these populations? Join host Geoff Wall with guest Dr. Matt Trump as they discuss the PREPARE trial.

The GameChanger
Emerging data suggests that using a bronchodilator with an inhaled corticosteroid (ICS) may improve asthma exacerbation symptoms in diverse patient populations. This is contrary to current standards of care that encourage the use of a short-acting bronchodilator alone. 

 Show Segments

00:00 – Introduction
02:05 – Asthma in Diverse Populations
04:25 – Inhaled Corticosteroids in Asthma Management 
06:50 – PREPARE Trial                                                                                   
18:33 – The GameChanger
28:11 – Closing Remarks 

Host

Geoff Wall, PharmD., BCPS, FCCP, CGP
Professor of Pharmacy Practice, Drake University
Internal Medicine/Critical Care, UnityPoint Health

Guest

Dr. Matt Trump, DO, FACP, FCCP
Pulmonary & Critical Care Specialist
The Iowa Clinic

Dr. Trump is a consultant for Fishter and Paykel Healthcare and an investigator for Astra Zeneca. 

All relevant financial relationships have been mitigated.

References and Resources

Reliever-Triggered Inhaled Glucocorticoid in Black and Latinx Adults with Asthma 

Redeem CPE or CME

Redeem CPE (Pharmacists)
Redeem CME (Prescribers)

Get a membership & earn CE for GameChangers Podcast episodes (30 mins/episode)

Pharmacists: Get a membership
Prescribers: Get a membership

CE Information

Learning Objectives

Upon successful completion of this knowledge-based activity, participants should be able to:

1.     Describe the disparity of outcomes in asthma between different demographics

2.     Discuss the role of reliever inhaled glucocorticoids for persons with asthma

0.05 CEU/0.5 Hr
UAN: 0107-0000-22-176-H01-P
Initial release date: 04/25/2022         
Expiration date: 04/25/2023
Additional CPE and CME details can be found here.

Follow CEimpact on Social Media:
LinkedIn
Instagram